Brief Description
Frontier Medicines was founded to develop medical treatments for currently "undruggable" diseases. The clinical stage precision medicine company pioneers medicines for genetically-defined patient populations in oncology and immunology, and plans to broaden its therapeutic focus over time. The company uses chemoproteomics - an innovative approach to chemically interrogate proteins in living systems – to discover and pharmacologically target new binding pockets (or "hotspots") on proteins, making them accessible to small-molecule drug discovery and development. The platform leverages covalent chemistry and machine learning to unlock hard-to-treat disease causing proteins for drug development.
Frontier Medicines was founded by a team of experts in chemoproteomics, cancer biology and company building: UC Berkeley Associate Professor of Chemistry, Molecular and Cell Biology, and Nutrional Sciences and Toxicology Daniel Nomura, PhD, UC Berkeley Assistant Professor of Molecular and Cell Biology Roberto Zonco, PhD, and CEO Chris Varma, PhD.
Timeline
- 2018. Company founded.
Inventors
Dan Nomura, Benjamin Fontaine, Sin Ki Fung, Chris Kumar Varma, Carl Ward, Roberto Zoncu